NR4A1 and breast cancer: To guide treatment decision in patients with LM, clinicians can take into consideration the prognostic Curie score that integrates performance status, the number of chemotherapy (CT) regimens prior to LM diagnosis and negative hormone receptor status, and, in patients with LM from BC, the breast graded prognostic assessment (Breast-GPA) initially validated in patients with BC brain metastases (BCBM) (13).